Zviuru zvemadhora eCOVID-19 Indian generic mishonga yakatengeswa kunze?chenjera!

1. Zviuru zvemadhora eCOVID-19 Indian generic mishonga yatengeswa kunze?chenjera!

Munguva pfupi yapfuura, musoro we "COVID-19 Indian generic drugs wakatengeswa nezviuru zveyuan mubhokisi" wakaonekwa pane yakakurumbira microblog yekutsvaga rondedzero.Mimwe mishonga yakatengwa pachinzvimbo cheChina News Network, uye masheya acho akange atengeswa, saka zvaive zvakakodzera kuti uatore svondo risati rasvika.Vanachiremba vanoyeuchidza kuti mishonga haifaniri kutengwa kuburikidza nenzira dzisina kurongwa.Pamusoro pezvo, mapoka asiri ane njodzi huru haafanire kushandisa COVID-19 mushonga wemukanwa.

Mutengo wepakutanga webhokisi remishonga i2300 yuan, uye mutengo wekutenga muIndia i1600 yuan.

"Iye zvino maodha azara."Vazhinji vekuIndia vanotenga zvinodhaka vakaudza chinanews.com kuti yavo Pfizer COVID-19 oral Paxlovid generic mishonga yakatengeswa nguva pfupi yadarika.Kana zvichidikanwa, vanogona chete kubhadhara dhipoziti kutanga, uye zvinhu zvinogona kuendeswa muvhiki pakutanga, kana mwedzi unotevera pane inononoka.

Kana mazwi ekuti "COVID-19 India", "COVID-19 generic drugs" zvichingodaro akaiswa pa-e-commerce papuratifomu, vatengi vanogona kukurumidza kuwana ruzivo rweava vatengi vanotenga, asi ivo vanowanzoda kuwedzera WeChat shamwari, uye. wobva wazivisa ruzivo rwezvinhu zvakananga uye zvinodiwa zvekutenga.

Mishonga yePaxlovid inotengeswa nevamiririri ava inosanganisira Primovir mupakeji yegirinhi uye Paxista mupakeji yebhuruu.Iyo yekutanga inogadzirwa neAstrica, kambani yeIndia, nepo yekupedzisira ichigadzirwa neAzista, mubatsiri weIndia bhizinesi remishonga Hetero.Parizvino, Primovir ine green packaging yakamira kugadzirwa, uye chete Paxista ine blue package ichiri kutengeswa.

Mumwe mumiririri akazivisa kuti mutengo wetsamba dzepamusha waive 1600 yuan pabhokisi, uye uyo wekutumira tsamba mhiri kwemakungwa waive 1200 yuan pabhokisi, 400 yuan yakachipa.Mutengo wekutenga wePaxlovid kuChina i2300 yuan pabhokisi.

Mishonga iyi yakaoma kutenga muzvitoro parizvino.Zvinoenderana nekutenga kwemumiririri wepamusoro, kuchengetedza kunogamuchirwa, uye tsamba yeIndia yakananga ichasvika muChina mukati memazuva gumi nemashanu kusvika makumi maviri.Akakurudzirawo kuti munhu wese angotenga mabhokisi maviri chete.

Vanachiremba vanoyeuchidza: Zvakaoma kutaura chokwadi kubva kune chenhema.Ramba wakangwarira

Muchokwadi, Paxlovid yagara ichishandiswa mukurapa hutachiona hweCCIDID-19 kuChina, asi inonyanya kushandiswa mune zvimwe zvipatara zvakatarwa uye inoda mvumo yemirairo yavanachiremba.Hazvisi zvipatara zvese zvine mushonga.

Zvakakosha kucherechedza kuti mamwe mageneric drug anotengeswa pakomisheni anogona kutengwa pasina kana kupa gwaro.Panyaya iyi, vanachiremba vane unyanzvi vanoyeuchidza munhu wose kuti ave akangwarira.

“Sevanachiremba vane hunyanzvi, hatikurudzire kutenga zvekunyepedzera kune dzimwe nyika, nekuti zvinonetsa kutaura chokwadi kubva kune chenhema.Zhang Jiming, mutevedzeri wemukuru weNational Infectious Diseases Medical Center uye chiremba mukuru, purofesa uye chiremba wepamusoro wechipatara cheHuashan chakabatana neFudan University, akaudza chinanews.com kuti vamwe varwere vaakabvunzurudza kana mhuri dzavo vakatenga zvekutevedzera vari voga, uye vainetseka kuti vari kutenga mishonga yemanyepo.Vakataura kuti zvakanga zvakaoma kuona mhando yemishonga yemazuva ano kubva kwaibva uye nekuchengetedzwa kwemamiriro ekuchengetedzwa kwemishonga kana tichitenga mishonga yegeneric kubva kunze kwenyika.

Zhang Jiming akazivisa kuti COVID-19 mushonga wemukanwa unonyanya kushandiswa kumapoka ane njodzi zvakanyanya kudzivirira zvirwere zvakakomba, uye inogona kushanda chete kana ikashandiswa kare.Mapoka asina ngozi zvikuru haafaniri kumhanyira kutenga, uye kubatwa zvisina kufanira kungaita kuti zvinodhaka zvisarambe.Izvo zvakare hazvina basa kukiriniki, nekuti vazhinji varwere vane asymptomatic kana hunyoro, uye nzira yechirwere inongogumira.

Akaudza vechina.com kuti, maererano nemamiriro ezvinhu muShanghai, zvipatara zvikuru, COVID-19 zvipatara zvakatemerwa uye mamwe masangano ekurapa kazhinji ane huwandu hwemishonga inorwisa COVID-19, iyo inoshandiswa nemapoka ane njodzi anosangana nezviratidzo uye ari kubatwa neCOVID-19, kuitira kudzivirira chirwere chakakomba uye kuderedza huwandu hwevanhu vanofa.

Pamusoro pezvo, sekureva kwenhau, vashandi vezvemitemo vanoyeuchidza kuti Indian COVID-19 generic mishonga inotengeswa pamhepo haisati yatenderwa muChina.Pasi pemutemo weDrug Administration Law wePeople's Republic of China, kunyange hazvo mishonga yakanyorwa kunze kwenyika asi isina kupihwa mvumo neChina haisati yangoonekwa semishonga yemanyepo, vanoishandisa vachakarirwa zvirango zvehurumende pavanopinza zvinodhaka kunze kwenyika zvisiri pamutemo.

2.Xinlitai aenda!Kubata maviri bhiriyoni mhando, gumi neimwe mhando dzeClass 1 mishonga mitsva.

Munguva pfupi yapfuura, Xinlitai R&D pombi yakafambira mberi.Mapiritsi ekutanga emushonga SAL0133 akaiswa kuti ashandiswe mukiriniki.Preliminary statistical analysis results yakawanikwa kubva kuPhase Ib clinical trial yePCSK9 monoclonal antibody.Kubva 2022, Xinlitai yakanyorera IND/NDA yemishonga minomwe yekuvandudza, uye tsvakiridzo yekuvandudza nekusimudzira yakasimudzirwa.Parizvino, Xinlitai ine maviri bhiriyoni emhando dzakasiyana, makumi maviri nemaviri ayo akaongororwa (8 ndiwo ekutanga);Mishonga makumi maviri neimwe iri kutsvagirwa, mitanhatu yacho iri muchikamu chekiriniki cheNDA kana Phase III, uye pombi yekuvandudza yapinda munguva yekubvisa mari.

Broad spectrum COVID-19 Mushonga Wemuromo Unooneka!Xinlitai Inopinda muCOVID-19 Circuit

Musi waZvita 20, Xinlitai akazivisa kuti kushandiswa kwekiriniki kweSAL0133, diki molecule inovandudza mushonga yakazvimiririra yakagadziriswa nekambani, yakagamuchirwa neState Food and Drug Administration.SAL0133 inhibitor ine simba, yakafara-spectrum anti novel coronavirus 3CL protease (3CLpro) yakazvimiririra kugadzirwa uye yakagadziridzwa nekambani ine yakazvimirira kodzero yepfuma yeruzivo.Parizvino, chiratidzo chekiriniki chichagadziridzwa ndechekurapa munhu mukuru akapfava/akajairwa novel coronavirus pneumonia (COVID-19).

3CLpro inoita basa rakakosha muRNA kudzokorodza kweinoveli coronavirus, kunyanya mudanho rekutanga rekudzokorora mushure mekunge hutachiona hwapinda muchitokisi, ichivharira kuita kwe3CLpro protease, iyo inogona kuvharisa kudzokororwa kwehutachiona uye kuita basa reanti novel coronavirus.

SAL0133 ine nzira yakajeka yekuita, uye ine yakasimba, yakafara-spectrum anti COVID-19 mhedzisiro.Zvinotarisirwa kuti hazvidi kusanganiswa neCYP3A4 inhibitor ritonavir, uye njodzi inogona kuitika yekubatana kwezvinodhaka yakaderera;Zvinotarisirwa kuwana kiriniki yekushandiswa kwezvinodhaka kamwe chete pazuva uye kuvandudza kutevedza kwemishonga yevarwere.Kana ichigona kugadzirwa zvakabudirira uye kubvumidzwa kushambadzira, ichapa varwere sarudzo itsva dzemishonga kuti vasangane nezvisina kuenderana nekiriniki zvinodiwa.

Tsvagiridzo uye kusimudzira kwe3CL yakanangana neCCIDID-19 yemuromo diki molecule mishonga yakwezva kutarisisa.Parizvino, Pfizer's Paxlovid chete ndiyo yakatenderwa kushambadzira munyika.Anopfuura gumi emabhizinesi emishonga emudzimba uye masangano ekutsvagisa sainzi anga achiita tsvakiridzo nekuvandudza 3CL yakanangana neCCIDID-19 mishonga, kusanganisira FB2001 yeFrontier Biology, VV993 yeJunshi Biology/Wangshan Wangshui, SIM0417 yePioneer Pharmaceutical, RAY1216 Pharmaceutical mapiritsi eZhonggutical GST-HG171 yeGuangshengtang, nezvimwe.

Nemarudzi maviri makuru bhiriyoni ari muruoko, mishonga 7 yemhando itsva gore rino inogamuchira kufambira mberi kutsva

Kunopera kwa2022, semumiriri weR&D shanduko muindasitiri yemishonga, Xinlitai akabudirira kuwana nzira yake yekuvandudza pasi pekumanikidzwa uye kugadzirisa.

Muzvikamu zvitatu zvekutanga zve2022, mari yekambani yaive 2.548 bhiriyoni yuan, nekukura-pagore kwe16.5%, uye purofiti yayo yaive 539 miriyoni yuan, nekukura-pagore kwe37.64%.Kuita kwakanaka kwakaisa hwaro hwakasimba hwebudiriro yakatevera.Kambani iyi inotarisira kuti muna 2022, Taijia (mapiritsi eclopidogrel bisulfate) achawana mari inosvika bhiriyoni imwe chete, uye Sinritan (mapiritsi ealisartan) achawana mari inosvika 900 miriyoni kusvika pabhiriyoni imwe chete yeyuan.Kambani iyi ine mhando makumi maviri nembiri, 8 dzacho dziri dzekutanga muChina.

Muna 2019, mhando huru yeXinlitai, Taijia, yakarasikirwa nekutenga kwayo mukutenga kwepakati pe4+7, izvo zvakamanikidza Xinlitai kuita shanduko.Mushumo wegore ra 2019, Xinlitai akazivisa kuti "pombi yekutsvagisa ichagadziriswa zvine hungwaru, uye anti-tumor biological analog uye maantibioti mapurojekiti mune mamwe matanho ekiriniki achamiswa".Muna 2020, kuitira kuti tiwedzere kukwidziridza pombi pasi pekutsvagisa uye kutarisa kuR&D nekusimudzirwa kwezvigadzirwa zvitsva, Xinlitai akatamisa kodzero uye zvido zvedapoxetine hydrochloride, erlotinib hydrochloride, rivasaban nemamwe mapurojekiti, uye akatambira mari yekufambisa.

Mushure mezvimwe zvigadziriso, pari zvino, pombi yemishonga yegeneric yeXinritai inongori neKirasi 4 yekushambadzira application yekuteedzera mahwendefa eSakubatrovalsartan sodium iri kuongororwa, uye iyo yekuwedzera application yekuenderana kuongororwa kwecefuroxime sodium yejekiseni uye cefotaxime sodium yejekiseni iri kuongororwa.Zvakakodzera kuti titaure kuti kubva muna Chikunguru 2019, Xinlitai haana kunyorera mishonga mitsva yegeneric kweanopfuura makore matatu, uye akawedzera kuisa pfungwa pakuvandudza nekutsvaga.

Kubva 2022, Xinlitai akaenderera mberi nekufambira mberi mukutsvagisa nekuvandudza kwemishonga yekuvandudza.Musi wa4 Ndira, 2022, kunyorwa kwekushandiswa kweCINRITAI's HIF-PHI inhibitor Enasitar mahwendefa akaitwa neCDE;Zvadaro, Kambani yakatumira zvikumbiro zvekiriniki zvemishonga mitsva mishanu yeClass 1, inoti, recombinant human neuromodulin-1 anti HER3 antibody fusion protein injection, mapiritsi eSAL0112, jekiseni reSAL008, mapiritsi eSAL0119 uye mapiritsi eSAL0133;Musi waMbudzi 3, kirasi itsva 2.3 yakavandudza mushonga wealisartan uye amlodipine mapiritsi eSINRITAI yakatumira chikumbiro chekunyora, iyo inotarisirwa kuumba hurongwa hwekubatana nekirasi yakanyorwa 1.1 antihypertensive drug SINRITAI.

JinDun Medicaline yenguva refu yekutsvagisa kwesainzi kushandira pamwe uye tekinoroji kubatanidza nemayunivhesiti eChinese.Nezviwanikwa zvekurapa zveJiangsu zvakapfuma, ine hukama hwekutengesa kwenguva refu neIndia, Southeast Asia, South Korea, Japan nemimwe misika.Inopawo musika uye masevhisi ekutengesa mukuita kwese kubva pakati kusvika pakupera chigadzirwa API.Shandisa zvakaunganidzwa zviwanikwa zveYangshi Chemical mune fluorine chemistry kupa akakosha makemikari ekugadzirisa masevhisi kune vanobatana.Ipa maitiro ekuvandudza uye kusachena kwekutsvaga masevhisi kune kunanga vatengi.

JinDun Medical inoomerera pakugadzira timu ine zviroto, kugadzira zvigadzirwa zvine rukudzo, zvine hungwaru, zvine hungwaru, uye kuenda zvese kunze kuti ive shamwari yakavimbika uye shamwari yevatengi! One stop solution vanopa, yakagadziridzwa R&D uye customized kugadzirwa masevhisi emishonga vepakati uye APIs, professionalcustomized pharmaceutical production(CMO) uye yakasarudzika mishonga yeR&D uye kugadzira (CDMO) vanopa masevhisi.Jindun achakuperekedza kunopedza COVID-19.